John at 19:45, 4 July 2023

2023-07-04T19:45:25Z

← Older revision		Revision as of 21:45, 4 July 2023
Line 59:		Line 59:
	\|-		\|-
	!colspan="8"\|'''Expression in mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%*		\|style="width: 12.5%; background: #004466; color:white"\|80-100%*
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John at 11:11, 3 July 2023

2023-07-03T11:11:52Z

← Older revision		Revision as of 13:11, 3 July 2023
Line 38:		Line 38:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|~~<span style="font-size:100%">~~'''Expression in primitive cell types'''</font>		!colspan="8"\|'''Expression in primitive cell types'''</font>
	\|-		\|- <span style="font-size:70%">
	! AML !! CMML !! B ALL !! ~~Burkitt~~ \|\| T ALL !! ETP ALL ~~<'''[[ETP ALL\|I]]'''>~~ !! ~~MPAL <'''[[~~MPAL~~\|I]]'''>~~ \|\| ~~Hgns~~ <~~'''[[Hgns\|I]]'''~~>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%*		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%*
	\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%

John at 08:42, 7 June 2023

2023-06-07T08:42:40Z

← Older revision		Revision as of 10:42, 7 June 2023
Line 93:		Line 93:

	----		----



	~~summary tables~~

	~~1. expression by acute leukaemias and by haematogones file~~
	~~freq pro-b all~~
	~~hi early pre-b all~~
	~~hi pre-b all~~
	~~hi early b all~~
	~~rare pro-t all~~
	~~rare mature-t all~~
	rare aml *
	~~hi haemato-gones~~

	~~2. expression by b-lymphoproliferative disorders~~
	hi cll *
	hi pll**
	~~hi mcl~~
	~~hi fl~~
	hi hcl**
	~~hi hclv~~
	~~hi mzl~~
	~~poss lpl~~
	~~rare pcs~~
	* typically weak ** typically strong

John: Created page with "
:'''Summary''' :CD79b is a pan-B-cell marker expressed from early commitment to B-cell lineage then becoming lost during plasma cell differentiation; CD79b may be used as marker of B-cel lineage, but its more variable expression make it less useful than CD79a or CD19 in this context :The major diagnostic value of CD79b is its characteristi..."

2023-06-07T08:41:54Z

Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :'''Summary''' :CD79b is a pan-B-cell marker expressed from early commitment to B-cell lineage then becoming lost during plasma cell differentiation; CD79b may be used as marker of B-cel lineage, but its more variable expression make it less useful than CD79a or CD19 in this context :The major diagnostic value of CD79b is its characteristi..."

New page

<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">

:'''Summary'''

:CD79b is a pan-B-cell marker expressed from early commitment to B-cell lineage then becoming lost during plasma cell differentiation; CD79b may be used as marker of B-cel lineage, but its more variable expression make it less useful than CD79a or CD19 in this context
:The major diagnostic value of CD79b is its characteristically weak-expression in CLL

</div>

'''Normal expression and function'''

The two forms of CD79 (CD79a and CD79b) each associate directly with the immunoglobulin chains to control signalling from the B-cell receptor. Expression of both CD79a and CD79b is therefore acquired at early B-lymphocyte formation (initially in cytoplasm then membrane) and persist until plasma cell differentiation. However, while both CD79a and CD79b may be considered pan B-cell antigens, expression of CD79b is acquired later and is lost earlier than for CD79a.

'''Diagnostic role'''

*The most useful attribute of CD79b is its variable intensity of expression - in particular the characteristically weak intensity of expression of CD79b in CLL is often used as a diagnostic criterion

----

'''''SUMMARY TABLES'''''

'''Note''' The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click [[Key to marker expression table|here]]. For further information about a particular disease state click <'''I'''> adjacent to the condition name

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in primitive cell types'''
|-
! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
|-
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%*
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%**
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #00b8e6; color:white"|40-80%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|-
|}

'''Notes:''' ''**''While a good marker of B lineage it may not be expressed in more primitive phenotype ALL, there is also a recognised abberrant expression in AML (particularly cases with t)8;21) 

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #004466; color:white"|80-100%*
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%**
|style="width: 12.5%; background: #004466; color:white"|80-100%**
|style="width: 12.5%; background: #00b8e6; color:white"|40-80%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%***
|-
|}

'''Notes:''' Level of expression is important: *low expression in CLL; **typically high expression in HCL; ***generally absent in PCs 

{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''Expression in mature T cell neoplasms*'''
|-
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|-
|}

----

summary tables

1. expression by acute leukaemias and by haematogones file
freq pro-b all
hi early pre-b all
hi pre-b all
hi early b all
rare pro-t all
rare mature-t all
rare aml *
hi haemato-gones

2. expression by b-lymphoproliferative disorders
hi cll *
hi pll**
hi mcl
hi fl
hi hcl**
hi hclv
hi mzl
poss lpl
rare pcs
* typically weak ** typically strong

CD79b - Revision history

John at 19:45, 4 July 2023

John at 11:11, 3 July 2023

John at 08:42, 7 June 2023